{"id":40303,"date":"2025-08-28T15:34:20","date_gmt":"2025-08-28T07:34:20","guid":{"rendered":"https:\/\/flcube.com\/?p=40303"},"modified":"2025-08-28T15:34:20","modified_gmt":"2025-08-28T07:34:20","slug":"nhsa-2025-drug-catalog-review-6-drugs-rejected-718-applications-reviewed","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40303","title":{"rendered":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed"},"content":{"rendered":"\n<p>The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes for the 2025 National Health Insurance Drug Catalog. Six drugs had their review status changed, all involving the Basic Health Insurance Drug Catalog.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-drug-status-changes\">Key Drug Status Changes<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>New Review Result<\/th><th>Reason \/ Criteria Met<\/th><\/tr><\/thead><tbody><tr><td><strong>Risperidone Microspheres for Injection<\/strong><\/td><td><strong>Failed<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>Triptorelin Pamoate for Injection<\/strong><\/td><td><strong>Failed<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>Levodopa Injection<\/strong><\/td><td><strong>Passed<\/strong><\/td><td>Meets <strong>Criteria\u202f5<\/strong> (rare\u2011disease drug approved before\u202f30\u202fJun\u202f2025)<\/td><\/tr><tr><td><strong>Calcium Gluconate and Sodium Chloride Injection<\/strong><\/td><td><strong>Passed<\/strong><\/td><td>Meets <strong>Criteria\u202f2<\/strong> (new or significantly changed indication approved 01\u202fJan\u202f2020\u201130\u202fJun\u202f2025)<\/td><\/tr><tr><td><strong>Ceftriaxone\u202fSodium and Sulbactam\u202fSodium for Injection<\/strong><\/td><td><strong>Passed<\/strong><\/td><td>Meets <strong>Criteria\u202f2<\/strong> (new\/changed indication)<\/td><\/tr><tr><td><strong>Ursodeoxycholic Acid Oral Suspension<\/strong><\/td><td><strong>Passed<\/strong><\/td><td>Meets <strong>Criteria\u202f1,\u202f4,\u202f5<\/strong> (new generic name within 5\u202fyears; encouraged R&amp;D; rare\u2011disease drug approved before\u202f30\u202fJun\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-2025-catalog-application-totals\">2025 Catalog Application Totals<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Catalog<\/th><th>Total Applications<\/th><th>Generic Drug Names<\/th><th>Passed<\/th><th>Out\u2011of\u2011Catalog<\/th><th>In\u2011Catalog<\/th><\/tr><\/thead><tbody><tr><td><strong>Basic Health Insurance<\/strong><\/td><td><strong>718<\/strong><\/td><td><strong>633<\/strong><\/td><td><strong>535<\/strong><\/td><td><strong>311<\/strong><\/td><td><strong>224<\/strong><\/td><\/tr><tr><td><strong>Commercial Insurance Innovative<\/strong><\/td><td><strong>141<\/strong><\/td><td><strong>141<\/strong><\/td><td><strong>121<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Both Catalogs<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>79<\/strong><\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-this-means-for-stakeholders\">What This Means for Stakeholders<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharmaceutical Companies<\/strong>: 535 approvals out of 718 submissions indicate a high but selective acceptance rate; companies must strengthen evidence for rare\u2011disease and indication\u2011change submissions.<\/li>\n\n\n\n<li><strong>Healthcare Providers<\/strong>: New approvals for Levodopa, Ceftriaxone\/Sulbactam, and Ursodeoxycholic Acid expand therapeutic options, particularly for rare diseases and chronic conditions.<\/li>\n\n\n\n<li><strong>Patients &amp; Payers<\/strong>: A larger pool of approved drugs enhances coverage choices, potentially reducing out\u2011of\u2011pocket costs for chronic treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40305,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[101,67],"class_list":["post-40303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nationally-negotiated-drugs","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40303\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed\" \/>\n<meta property=\"og:description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40303\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T07:34:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed\",\"datePublished\":\"2025-08-28T07:34:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2808.webp\",\"keywords\":[\"Nationally negotiated drugs\",\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40303#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40303\",\"name\":\"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2808.webp\",\"datePublished\":\"2025-08-28T07:34:20+00:00\",\"description\":\"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40303\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2808.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2808.webp\",\"width\":1080,\"height\":608,\"caption\":\"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40303#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40303","og_locale":"en_US","og_type":"article","og_title":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed","og_description":"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.","og_url":"https:\/\/flcube.com\/?p=40303","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-28T07:34:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40303#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40303"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed","datePublished":"2025-08-28T07:34:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40303"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40303#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","keywords":["Nationally negotiated drugs","NHSA (prev. SMIA)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40303#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40303","url":"https:\/\/flcube.com\/?p=40303","name":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40303#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40303#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","datePublished":"2025-08-28T07:34:20+00:00","description":"China\u2019s National Healthcare Security Administration (NHSA) released the 2025 National Health Insurance Drug Catalog formal review results, noting six drug status changes, 718 Basic Health Insurance submissions, and 141 Commercial Insurance applications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40303#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40303"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40303#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","width":1080,"height":608,"caption":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40303#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2808.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40303"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40303\/revisions"}],"predecessor-version":[{"id":40306,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40303\/revisions\/40306"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40305"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}